1. Home
  2. RBOT vs KPTI Comparison

RBOT vs KPTI Comparison

Compare RBOT & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RBOT
  • KPTI
  • Stock Information
  • Founded
  • RBOT 2014
  • KPTI 2008
  • Country
  • RBOT United States
  • KPTI United States
  • Employees
  • RBOT N/A
  • KPTI N/A
  • Industry
  • RBOT Medical Specialities
  • KPTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • RBOT Health Care
  • KPTI Health Care
  • Exchange
  • RBOT Nasdaq
  • KPTI Nasdaq
  • Market Cap
  • RBOT 86.1M
  • KPTI 81.1M
  • IPO Year
  • RBOT N/A
  • KPTI 2013
  • Fundamental
  • Price
  • RBOT $12.40
  • KPTI $0.62
  • Analyst Decision
  • RBOT Hold
  • KPTI Strong Buy
  • Analyst Count
  • RBOT 2
  • KPTI 4
  • Target Price
  • RBOT $10.25
  • KPTI $5.00
  • AVG Volume (30 Days)
  • RBOT 35.7K
  • KPTI 679.6K
  • Earning Date
  • RBOT 03-03-2025
  • KPTI 02-27-2025
  • Dividend Yield
  • RBOT N/A
  • KPTI N/A
  • EPS Growth
  • RBOT N/A
  • KPTI N/A
  • EPS
  • RBOT N/A
  • KPTI N/A
  • Revenue
  • RBOT N/A
  • KPTI $148,442,000.00
  • Revenue This Year
  • RBOT N/A
  • KPTI $5.47
  • Revenue Next Year
  • RBOT N/A
  • KPTI $6.33
  • P/E Ratio
  • RBOT N/A
  • KPTI N/A
  • Revenue Growth
  • RBOT N/A
  • KPTI 1.77
  • 52 Week Low
  • RBOT $4.27
  • KPTI $0.58
  • 52 Week High
  • RBOT $19.00
  • KPTI $1.70
  • Technical
  • Relative Strength Index (RSI)
  • RBOT 51.16
  • KPTI 41.95
  • Support Level
  • RBOT $12.34
  • KPTI $0.60
  • Resistance Level
  • RBOT $14.05
  • KPTI $0.69
  • Average True Range (ATR)
  • RBOT 1.30
  • KPTI 0.05
  • MACD
  • RBOT -0.09
  • KPTI -0.00
  • Stochastic Oscillator
  • RBOT 30.30
  • KPTI 18.17

About RBOT Vicarious Surgical Inc.

Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: